Jacobs Levy Equity Management Inc. Has $2.88 Million Position in Codexis, Inc. $CDXS

Key Points

• Jacobs Levy Equity Management Inc. increased its stake in Codexis, Inc. by 24.3% during Q1, owning approximately 1.29% of the company worth $2.88 million.
• Institutional investors collectively own 78.54% of Codexis, indicating strong institutional interest in the company.
• After reporting earnings exceeding analyst estimates, Codexis currently holds a consensus rating of "Moderate Buy" with an average price target of $11.00.

Jacobs Levy Equity Management Inc. grew its position in shares of Codexis, Inc. (NASDAQ:CDXS - Free Report) by 24.3% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,070,253 shares of the biotechnology company's stock after buying an additional 209,298 shares during the quarter. Jacobs Levy Equity Management Inc. owned approximately 1.29% of Codexis worth $2,879,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently modified their holdings of CDXS. US Bancorp DE boosted its holdings in shares of Codexis by 11,125.0% in the 1st quarter. US Bancorp DE now owns 17,960 shares of the biotechnology company's stock worth $48,000 after acquiring an additional 17,800 shares in the last quarter. Wolverine Trading LLC bought a new position in Codexis in the 4th quarter valued at $56,000. Fiduciary Trust Co acquired a new position in Codexis in the fourth quarter worth $65,000. Group One Trading LLC bought a new stake in shares of Codexis during the fourth quarter worth $73,000. Finally, ProShare Advisors LLC increased its stake in shares of Codexis by 101.1% in the fourth quarter. ProShare Advisors LLC now owns 26,543 shares of the biotechnology company's stock valued at $127,000 after buying an additional 13,344 shares in the last quarter. Institutional investors own 78.54% of the company's stock.

Analyst Ratings Changes

Separately, Wall Street Zen upgraded shares of Codexis from a "strong sell" rating to a "hold" rating in a research report on Saturday, August 16th. One analyst has rated the stock with a Buy rating and one has given a Hold rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $11.00.

Codexis Stock Performance

Shares of CDXS opened at $2.45 on Wednesday. The stock's fifty day simple moving average is $2.82 and its 200-day simple moving average is $2.62. The firm has a market capitalization of $221.16 million, a PE ratio of -2.95 and a beta of 2.54. Codexis, Inc. has a 12-month low of $1.90 and a 12-month high of $6.08. The company has a quick ratio of 5.70, a current ratio of 5.82 and a debt-to-equity ratio of 0.71.

Codexis (NASDAQ:CDXS - Get Free Report) last announced its quarterly earnings data on Wednesday, August 13th. The biotechnology company reported ($0.16) earnings per share for the quarter, beating the consensus estimate of ($0.17) by $0.01. Codexis had a negative net margin of 113.67% and a negative return on equity of 105.83%. The business had revenue of $15.33 million for the quarter, compared to analyst estimates of $14.18 million. As a group, research analysts predict that Codexis, Inc. will post -0.77 earnings per share for the current year.

Codexis Profile

Codexis, Inc discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes.

Want to see what other hedge funds are holding CDXS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Codexis, Inc. (NASDAQ:CDXS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.